The stakes of this seemingly academic quarrel are enormous. Obstructive sleep apnea affects roughly a billion people worldwide by some estimates, and its overlap with obesity is so pervasive that the two conditions are often treated as two faces of the same metabolic syndrome. Yet the causal architecture linking them remains surprisingly murky. If clinicians cannot quantify how much of a given patient’s apnea is adiposity-attributable, they cannot accurately predict how much that patient will benefit from weight loss, whether through lifestyle intervention, pharmacotherapy such as the new generation of incretin-based drugs, or bariatric surgery. That uncertainty ripples directly into treatment decisions, insurance coverage, and the design of clinical trials.

At the heart of the exchange is a concept that sleep researchers call endotypes, the distinct physiological mechanisms that produce the shared clinical picture of repetitive upper airway collapse during sleep. Schmickl, Malhotra and their colleagues had previously argued, in their review “Sleep and obesity: known interactions and open questions,” that obesity acts on sleep apnea through multiple parallel pathways: it narrows the pharyngeal airway through fat deposition around the neck and tongue, it reduces lung volume and thereby diminishes the tracheal tug that stiffens the upper airway, it destabilizes respiratory control by increasing loop gain, and it alters arousal thresholds and fluid shifts that further compromise airway patency during sleep. Weight loss, in this view, does not simply shrink a pipe; it reconfigures an entire physiological system.

The Maizura commentary, in turn, pressed the field to go further and define what fraction of apnea severity is genuinely attributable to adiposity rather than merely coexisting with it. The distinction matters because correlation between body mass index and apnea severity, while real, is notoriously imperfect. Many patients with severe obesity never develop sleep apnea, and many lean patients do. Craniofacial anatomy, upper airway muscle responsiveness, genetic predisposition, and age all modulate the relationship. The commentators argued that without a formal definition of adiposity-attributable disease, the field risks overestimating the benefits of weight-targeted therapies and underdiagnosing the apnea that persists after the pounds come off.

Schmickl and Malhotra’s reply, accepted by the journal in September 2026, engages this critique directly. While the published reply is brief, its positioning within the citation trail reveals its argumentative center of gravity: the authors point to recent work by Beatty and colleagues, published in Chest, that measured how weight loss reshapes the physiological endotypes of obstructive sleep apnea. That study provides some of the most direct evidence to date that reducing adiposity produces measurable, mechanistically specific changes in airway collapsibility, loop gain, and arousal threshold, rather than a diffuse or nonspecific improvement. In other words, the causal pathways that obesity exploits are identifiable, quantifiable, and reversible, which is precisely the kind of evidence needed to move from coexistence to causation.

The reply also draws on a foundational observation from Peppard, Ward and Morrell, who showed more than a decade and a half ago that obesity amplifies oxygen desaturation during sleep-disordered breathing independent of its effect on airway collapse itself. Fat tissue, particularly around the abdomen and chest wall, mechanically loads the respiratory system, reducing the oxygen reserves available when breathing pauses occur. Two patients with identical degrees of airway obstruction can therefore experience dramatically different falls in blood oxygen depending on their body habitus. This finding complicates any attempt to define adiposity-attributable apnea using the apnea-hypopnea index alone, because the index counts events but says nothing about their physiological consequences.

That limitation has driven a broader movement in the field toward measures such as the hypoxic burden, championed by Azarbarzin, Sands and colleagues in analyses of the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study. Their work demonstrated that the total burden of nocturnal oxygen deprivation predicts cardiovascular mortality better than the conventional event index, suggesting that the downstream harm of sleep apnea flows substantially through intermittent hypoxia. If adiposity disproportionately worsens hypoxic burden, then the fraction of apnea-related cardiovascular risk that is adiposity-attributable may exceed the fraction of apnea events that weight loss eliminates. Schmickl and Malhotra’s reply implicitly invokes this distinction, arguing that any definition of adiposity-attributable disease must grapple with severity measures that capture physiological consequence, not just event frequency.

The exchange also touches on a practical question that clinicians confront daily: what happens to sleep apnea after weight loss? Bariatric surgery cohorts and pharmacological trials consistently show substantial reductions in apnea severity, but remission is far from universal, and severity often recurs even when weight loss is maintained. The Beatty endotype study helps explain why. Weight loss preferentially improves certain mechanisms, such as airway collapsibility and lung volume effects, while leaving others, such as inherently narrow craniofacial anatomy or high loop gain driven by ventilatory control instability, largely untouched. A patient whose apnea was mostly anatomical may remain apneic after losing significant weight, while a patient whose apnea was mostly weight-driven may remit completely. Defining adiposity-attributable apnea, in this light, is less a semantic exercise than a prerequisite for personalized therapy.

Neither side of the dispute disputes the fundamental biology. Obesity is the single strongest modifiable risk factor for obstructive sleep apnea, and the epidemic of adiposity has been a principal engine of the global rise in sleep-disordered breathing. The disagreement is about epistemics: how confidently the field can assign causal fractions to a multifactorial disease when the contributing mechanisms interact, overlap, and compensate for one another. Schmickl and Malhotra, whose review emphasized the bidirectional nature of the relationship, note that the arrow also points the other way. Sleep apnea fragments sleep, promotes daytime sleepiness that reduces physical activity, and dysregulates hormones such as leptin and ghrelin that govern appetite, thereby promoting weight gain in a self-reinforcing loop. Any causal accounting that treats obesity as the sole upstream actor risks missing this feedback structure entirely.

The reply, published as volume 22, article 174 of the Journal of Clinical Sleep Medicine, is unlikely to settle the debate on its own, but it clarifies what a resolution would require: longitudinal studies that measure endotype-specific responses to defined amounts of weight loss, severity metrics that capture hypoxic and cardiovascular consequence, and analytical frameworks that can partition variance across interacting mechanisms. As incretin-based weight-loss therapies reshape the treatment landscape and millions of patients begin losing weight while still wearing their CPAP machines, the question of how much apnea the fat was actually causing will move from the pages of academic journals into the examination room. The Schmickl-Malhotra reply signals that the field’s leading sleep physiologists intend to answer that question with mechanistic precision rather than assumption, and the exchange it concludes may well be remembered as an early milestone in the effort to make sleep medicine genuinely causal in its reasoning.

Subject of Research: The causal relationship between adiposity and obstructive sleep apnea and its physiological endotypes

Article Title: Reply to “From coexistence to causation: defining adiposity-attributable obstructive sleep apnea”

Article References: Reply to “From coexistence to causation: defining adiposity-attributable obstructive sleep apnea”. (n.d.). https://doi.org/10.1007/s44470-026-00197-2

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00197-2

Keywords: obstructive sleep apnea, obesity, adiposity, endotypes, weight loss, hypoxic burden, loop gain, airway collapsibility, bariatric surgery, sleep medicine, CPAP, causation

The argument arrives at a moment when the biology linking fat tissue to disordered breathing has never been clearer. Excess adiposity contributes to apnea through several well-characterized mechanisms. Fat deposited around the neck and tongue narrows and stiffens the pharyngeal airway, reducing the space available for airflow even before a patient falls asleep. Fat accumulated in the abdomen pushes upward on the diaphragm when a person lies down, lowering lung volumes and with them the traction that normally holds the upper airway open. Beyond these mechanical effects, adipose tissue is metabolically active, secreting inflammatory cytokines and hormones that appear to blunt the responsiveness of the muscles that keep the throat patent during sleep. The result is a disease in which the burden of fat, distributed across the body and within the airway itself, directly determines how often breathing stops each night.

The scale of the association is striking. An individual participant data meta-analysis of four community-based cohorts covering 12,860 adults, published in EClinicalMedicine in 2025, quantified the relationship between obesity and obstructive sleep apnea across large general populations rather than specialized clinics. Studies of this kind show that increases in body mass index are consistently accompanied by rises in the apnea-hypopnea index, the standard measure of how many times per hour a sleeper’s airflow is partially or completely obstructed. Yet the letter’s authors emphasize that such population-level correlations, however robust, still describe association. A heavy person may develop apnea because of fat, or because of a naturally narrow jaw, enlarged tonsils, or craniofacial anatomy inherited independently of weight. Without a framework for separating these contributors, clinicians cannot say how much of any individual patient’s disease is truly adiposity-driven.

Why does that distinction matter now? Because for the first time, therapies exist that can remove adiposity from the equation and measure what happens to the airway. The SURMOUNT-OSA trial, reported in the New England Journal of Medicine in 2024, tested tirzepatide, a dual incretin agonist already approved for obesity and type 2 diabetes, in patients with moderate to severe obstructive sleep apnea. The drug produced substantial weight loss and, crucially, large reductions in the apnea-hypopnea index, demonstrating that pharmacologically shrinking the body’s fat burden can directly unburden the sleeping airway. In the letter’s framing, such results transform the obesity-apnea relationship from a statistical observation into an experimentally testable causal claim, and they create a practical imperative to know in advance which patients stand to benefit most.

Surgical evidence points in the same direction. Bariatric surgery produces some of the largest and most durable weight reductions available in medicine, and studies of apnea outcomes after these procedures have repeatedly documented meaningful falls in the apnea-hypopnea index. But the improvements are rarely complete, and a substantial fraction of patients retain diagnosable sleep apnea even after losing large amounts of weight. That incomplete remission is itself informative. It suggests that while adiposity is a dominant and modifiable driver of the disease in many patients, non-adipose factors, from fixed airway anatomy to ventilatory control instability, persist independently. A formal definition of adiposity-attributable apnea would give clinicians a way to predict, before surgery or drug therapy, how much of a patient’s apnea is likely to resolve with weight loss and how much will require ongoing treatment with positive airway pressure or other modalities.

The mechanistic detail is advancing rapidly at the tissue level. Work published in the American Journal of Respiratory and Critical Care Medicine in 2020 examined what actually changes in the upper airway when patients lose weight, with particular attention to tongue fat. The researchers found that reductions in tongue volume tracked with improvements in the apnea-hypopnea index, underscoring that the location of fat loss matters as much as the total amount. The tongue is a muscular organ infiltrated by fat in obesity, and increased tongue fat both enlarges the structure and impairs the function of the muscles that keep it from falling back into the throat during sleep. This finding reframes weight loss for apnea not as a diffuse systemic effect but as a targeted anatomical intervention: shrink the tongue, open the airway. It also hints that future imaging could measure tongue fat directly, giving clinicians a biomarker for the adipose component of an individual’s disease.

Against this backdrop, the letter’s central proposal is conceptual rather than experimental. The authors, writing from five Indonesian institutions, argue that the field should formally define and characterize adiposity-attributable obstructive sleep apnea as a distinct clinical entity, much as medicine distinguishes, for example, secondary hypertension driven by a specific cause from essential hypertension of multifactorial origin. Such a definition would need operational criteria: measures of adiposity, ideally including regional depots like neck circumference and tongue fat; evidence that airway obstruction varies with those measures; and, ultimately, demonstration that interventions reducing fat reduce the apnea. The authors frame this as a shift from coexistence to causation, insisting that the discipline stop treating the two conditions as merely frequent bedfellows and start quantifying how much of the sleep apnea epidemic is, in a rigorous sense, a complication of obesity.

The implications ripple outward across clinical practice and public health. Obstructive sleep apnea affects an estimated hundreds of millions of adults worldwide, and its consequences extend far beyond snoring and daytime fatigue: untreated apnea is linked to hypertension, cardiovascular disease, stroke, type 2 diabetes, and impaired cognition. The standard treatment, continuous positive airway pressure, is effective but burdensome, and long-term adherence is notoriously poor. If a meaningful share of apnea is adiposity-attributable, then weight management, whether through lifestyle intervention, incretin-based pharmacotherapy, or metabolic surgery, becomes not an adjunct to apnea care but a potential disease-modifying therapy in its own right. Conversely, patients whose apnea is largely independent of weight would be spared unrealistic expectations that shedding kilograms will cure their disorder, allowing earlier and more appropriate escalation to airway-based treatments.

The letter also engages with a broader scientific conversation about sleep and obesity. A 2026 review in the same journal by Schmickl and colleagues, including sleep medicine researcher Atul Malhotra, mapped the known interactions between the two conditions and the open questions that remain, noting that the relationship is bidirectional. Sleep apnea fragments sleep and induces intermittent hypoxia, both of which dysregulate appetite hormones and promote weight gain, creating a vicious cycle in which each condition feeds the other. Disentangling cause and effect in such a loop is genuinely difficult, and the letter’s authors acknowledge that a definition of adiposity-attributable apnea will need to grapple with this bidirectionality: apnea may worsen the obesity that worsens the apnea. Careful longitudinal designs and mechanistic studies will be required to separate the forward and reverse arcs of the cycle.

What the proposal ultimately demands is a change in how the field measures success. If adiposity-attributable apnea becomes a recognized construct, trials of weight-loss therapies would be expected to report not just average apnea reductions but the proportion of patients whose disease remitted entirely, and studies would stratify participants by markers of the adipose contribution to their airway disease. Insurers and health systems, in turn, might one day cover weight-loss interventions for apnea on the same footing as airway pressure devices, justified by evidence that they address a root cause rather than a symptom. The letter, published on 24 August 2026 as volume 22, article 146 of the Journal of Clinical Sleep Medicine, is a call to sharpen a relationship that clinicians have taken for granted for decades. Its authors argue that the tools to do so, from incretin agonists and metabolic surgery to tongue-fat imaging and population-scale meta-analysis, already exist. What remains is the conceptual work of defining exactly when a disease of the sleeping airway is, at its core, a disease of fat.

Subject of Research: The causal role of adiposity in obstructive sleep apnea and the proposal to define adiposity-attributable sleep apnea as a distinct clinical entity

Article Title: From coexistence to causation: defining adiposity-attributable obstructive sleep apnea

Article References: Maizura, N., Andrianie, S., Bariyyah, K., Soejanto, L. T., Putri, S. N. J., & Ariyanto, R. D. (2026). From coexistence to causation: defining adiposity-attributable obstructive sleep apnea. Journal of Clinical Sleep Medicine, 22(1), Article 146. https://doi.org/10.1007/s44470-026-00175-8

Image Credits: AI Generated

DOI: 10.1007/s44470-026-00175-8

Keywords: obstructive sleep apnea, obesity, adiposity, tirzepatide, bariatric surgery, tongue fat, apnea-hypopnea index, sleep medicine, weight loss, upper airway, causation, metabolic health